Designed for theranostic imaging applications, the AnyScan Trio SPECT/CT TheraMax scanner was recently unveiled at the annual meeting of the European Association of Nuclear Medicine (EANM).
Offering enhanced sensitivity and spatial resolution capability approaching that of positron emission tomography (PET), the AnyScan Trio SPECT/CT TheraMax system was introduced at the European Association of Nuclear Medicine (EANM) annual conference in Hamburg, Germany.
Designed with an emphasis on targeted radionuclide therapy applications, the AnyScan Trio SPECT/CT TheraMax platform includes detectors and collimators that enable the use of alpha- and beta-emitting radiopharmaceuticals as well as high-energy gamma photons such as lutetium-177 (177Lu) and actinium-225 (225Ac), according to Mediso, the manufacturer of the AnyScan Trio SPECT/CT TheraMax device.
The company noted that other features and capabilities of the system include:
• surface detectors up to five times larger than those utilized in 12-detector cadmium zinc telluride (CZT) platforms;
• PET-like image quality with bolstered spatial resolution facilitated by the platform’s high-density sensor arrangement;
• whole-body SPECT/CT scans with up to 300 percent higher sensitivity in comparison to conventional dual-detector devices; and
• integrated computed tomography (CT) options for low-dose, ultra-low dose and “zero-dose” protocols with artificial intelligence (AI)-enabled SyCT (Synthetic CT).
"With the development of the new TheraMAX, we extended the imaging capabilities of nuclear medicine departments by improving the diagnostic confidence of SPECT/CT examinations close to PET/CT," said Istvan Bagaméry, the managing director of Mediso. "The TheraMAX transforms the clinical routine also with ultra-fast quantitative total-body scans."
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.